Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 4, 2018
- Accepted in final form November 26, 2018
- First Published March 7, 2019.
Author Disclosures
- Baptiste Pasquier,
- Nadja Borisow, MD,
- Ludwig Rasche, MD,
- Judith Bellmann-Strobl, MD,
- Klemens Ruprecht, MD,
- Thoralf Niendorf, MD, PHD,
- Tobias J. Derfuss, MD,
- Jens Wuerfel, MD,
- Friedemann Paul, MD* and
- Tim Sinnecker, MD*
- Baptiste Pasquier,
NONE
NONE
(1) ECTRIMS-conference Travel Grant,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nadja Borisow, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ludwig Rasche, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Judith Bellmann-Strobl, MD,
NONE
NONE
speaking fees and travel grants from Bayer Healthcare, sanofi-aventis/Genzyme, Merck and Teva Pharmaceuticals
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klemens Ruprecht, MD,
(1)sanofi-aventis/Genzyme (2)Novartis (3)Roche
NONE
(1)Bayer Healthcare, travel and speaker honoraria (2)Biogen Idec, travel and speaker honoraria (3)Merck Serono, travel and speaker honoraria (4)sanofi-aventis/Genzyme, travel and speaker honoraria (5)Teva Pharmaceuticals, travel and speaker honoraria (6)Novartis, travel and speaker honoraria (7)Guthy Jackson Charitable Foundation, travel honoraria
(1) PLOS ONE, Academic Editor, since 2013
NONE
(1) Neurologie in Frage und Antwort, Elsevier, 2000-2015
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Merck Serono
(1)German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Thoralf Niendorf, MD, PHD,
NONE
NONE
Siemens Healthcare, Erlangen Germany funding for travel
Magnetic Resonance Materials in Physics, Biology and Medicine Guest editor for the special issue on ultrahigh field MR 2015-2016 Guest editor for the special issue on fluorine MRI 2018- 2019
NONE
NONE
NONE
NONE
NONE
I am founder and CEO of MRI.TOOLS GmbH, Berlin, Germany
NONE
Siemens Healthcare, Erlangen, Germany
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias J. Derfuss, MD,
Scientific advisory boards for (1) Biogen (2) Novartis (3) Genzyme (4) Merck (5) Bayer (6) Octapharma (7) GeNeuro (8) Roche (9) Actelion (10) Celgene
NONE
travel and speaker honoraria from (1) Bayer (2) Biogen (3) Merck (4) Novartis (5) Genzyme (6) Roche
Member of the Editorial board of Plos One
NONE
NONE
My wife is an employee of Novartis.
Member of steering committee in Phase II studies by Mitsubishi Pharma and by GeNeuro
(1) Biogen (2)Novartis (3) Merck
Member of the Executive board of ECTRIMS (non-profit entity)
NONE
(1) Novartis (2) Biogen
(1)PI of a projected funded by the Swiss National Foundation
NONE
(1) Swiss MS Society
NONE
NONE
NONE
My wife owns stocks option from Novartis
NONE
NONE
- Jens Wuerfel, MD,
2011: Novartis advisory board 2014: Biogen, Novartis advisory board 2015: Genzyme, Teva advisory board 2016: Genzyme, Roche advisory board 2017: Genzyme, Roche advisory board
NONE
2011: Novartis travel support (AAN) 2012-2016: Bayer, Biogen, Novartis speaker honoraria
NONE
NONE
NONE
CEO, MIAC AG, Switzerland (non-profit organisation)
NONE
NONE
NONE
NONE
NONE
German ministry of education and research (BMBF/KKNMS), subinvestigator, 2013-2016; and the German ministry of economy (BMWi), EXIST program and EU (Horizon2020)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD* and
Novartis OCTIMS study steering committee MedImmune steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- Tim Sinnecker, MD*
NONE
NONE
(1) Actelion, travel support (2) Roche, travel support (3) Biogen, speaker honoraria
NONE
NONE
NONE
(1) MIAC, Basel, Switzerland
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neurologic Clinic and Policlinic (B.P., T.J.D., T.S.), Departments of Medicine, Clinical Research and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland; NeuroCure Clinical Research Center (N.B., L.R., J.B.-S., F.P., T.S.), Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (N.B., J.B.-S., K.R., F.P.), Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Experimental and Clinical Research Center (F.P.), Charité—Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine; Clinical and Experimental Multiple Sclerosis Research Center (K.R., F.P.), Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Berlin Ultrahigh Field Facility (T.N.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Germany; Medical Image Analysis Center AG (J.W., T.S.); and qbig (J.W.), Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
- Correspondence
Dr. Paul friedemann.paul{at}charite.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
What's Happening
What's happening in Neurology® Neuroimmunology & Neuroinflammationet al.Neurology, September 16, 2019 -
Views & Reviews
MRI characteristics of neuromyelitis optica spectrum disorderAn international updateHo Jin Kim, Friedemann Paul, Marco A. Lana-Peixoto et al.Neurology, February 18, 2015 -
Articles
Magnetization transfer imaging of patients with definite MS and negative conventional MRIM. Filippi, M.A. Rocca, L. Minicucci et al.Neurology, March 01, 1999 -
Articles
A longitudinal study of brain atrophy in relapsing multiple sclerosisJ.H. Simon, L.D. Jacobs, M.K. Campion et al.Neurology, July 01, 1999